BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schlickeiser S, Schwarz T, Steiner S, Wittke K, Al Besher N, Meyer O, Kalus U, Pruß A, Kurth F, Zoller T, Witzenrath M, Sander LE, Müller MA, Scheibenbogen C, Volk HD, Drosten C, Corman VM, Hanitsch LG. Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses. Front Immunol 2020;11:628971. [PMID: 33584731 DOI: 10.3389/fimmu.2020.628971] [Cited by in Crossref: 9] [Cited by in F6Publishing: 26] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Willeit P, Kimpel J, Winner H, Harthaller T, Schäfer H, Bante D, Falkensammer B, Rössler A, Riepler L, Ower C, Sacher M, von Laer D, Borena W. Seroprevalence of SARS-CoV-2 infection in the Tyrolean district of Schwaz at the time of the rapid mass vaccination in March 2021 following B.1.351-variant outbreak. Front Public Health 2022;10:989337. [DOI: 10.3389/fpubh.2022.989337] [Reference Citation Analysis]
2 Kim Y, Bae JY, Kwon K, Chang HH, Lee WK, Park H, Kim J, Choi I, Park MS, Kim SW. Kinetics of neutralizing antibodies against SARS-CoV-2 infection according to sex, age, and disease severity. Sci Rep 2022;12:13491. [PMID: 35931794 DOI: 10.1038/s41598-022-17605-1] [Reference Citation Analysis]
3 Schmidt AE, Vogel P, Chastain CA, Barnes T, Roth NJ, Simon TL. Analysis of 52 240 source plasma donors of convalescent COVID-19 plasma: Sex, ethnicity, and age association with initial antibody levels and rate of dissipation. J Clin Apher 2022. [PMID: 35815776 DOI: 10.1002/jca.21998] [Reference Citation Analysis]
4 Sherwani S, Khan MWA, Mallik A, Khan M, Saleem M, Raafat M, Shati AA, Alam N. Seroprevalence of Anti-S1-RBD Antibodies in Pre-pandemic and Pandemic Subjects From Hail Region, KSA. Front Public Health 2022;10:874741. [PMID: 35757607 DOI: 10.3389/fpubh.2022.874741] [Reference Citation Analysis]
5 Wirsching S, Harder L, Heymanns M, Gröndahl B, Hilbert K, Kowalzik F, Meyer C, Gehring S. Long-Term, CD4+ Memory T Cell Response to SARS-CoV-2. Front Immunol 2022;13:800070. [PMID: 35514974 DOI: 10.3389/fimmu.2022.800070] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Lu L, Yu S, Liu M, Li Y, Lei Q, Lin M, Lai D, Guo S, Jiang H, Hou H, Zheng Y, Wang X, Ma M, Zhang B, Chen H, Xue J, Zhang H, Qi H, Sun Z, Wang F, Fan X, Xu Z. SARS-CoV-2-specific antibody response characteristics in COVID-19 patients of different ages. Acta Biochim Biophys Sin (Shanghai) 2022;54:556-64. [PMID: 35607955 DOI: 10.3724/abbs.2022014] [Reference Citation Analysis]
7 Doke P, Gothankar JS, Doke PP, Kulkarni MM, Khalate KK, Shrivastava S, Patil JR, Arankalle VA. Time dependent decline of neutralizing antibody titers in COVID-19 patients from Pune, India and evidence of reinfection. Microbes Infect 2022;:104979. [PMID: 35452812 DOI: 10.1016/j.micinf.2022.104979] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Choi H, Jeon C, Won EJ, Kang S, Lee SY, Kee S. Performance of Severe Acute Respiratory Syndrome Coronavirus 2 Serological Diagnostic Tests and Antibody Kinetics in Coronavirus Disease 2019 Patients. Front Microbiol 2022;13:881038. [DOI: 10.3389/fmicb.2022.881038] [Reference Citation Analysis]
9 Labropoulou S, Vassilaki N, Milona RS, Terpos E, Politou M, Pappa V, Pagoni M, Grouzi E, Dimopoulos MA, Mentis A, Emmanouil M, Angelakis E. Characterizing Kinetics and Avidity of SARS-CoV-2 Antibody Responses in COVID-19 Greek Patients. Viruses 2022;14:758. [DOI: 10.3390/v14040758] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Steiner S, Schwarz T, Corman VM, Gebert L, Kleinschmidt MC, Wald A, Gläser S, Kruse JM, Zickler D, Peric A, Meisel C, Meyer T, Staudacher OL, Wittke K, Kedor C, Bauer S, Besher NA, Kalus U, Pruß A, Drosten C, Volk HD, Scheibenbogen C, Hanitsch LG. SARS-CoV-2 T Cell Response in Severe and Fatal COVID-19 in Primary Antibody Deficiency Patients Without Specific Humoral Immunity. Front Immunol 2022;13:840126. [PMID: 35359967 DOI: 10.3389/fimmu.2022.840126] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
11 Usai C, Gibbons JM, Pade C, Li W, Jacobs SRM, McKnight Á, Kennedy PTF, Gill US. The β-NGF/TrkA Signalling Pathway Is Associated With the Production of Anti-Nucleoprotein IgG in Convalescent COVID-19. Front Immunol 2021;12:813300. [PMID: 35095908 DOI: 10.3389/fimmu.2021.813300] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
12 Georg P, Astaburuaga-García R, Bonaguro L, Brumhard S, Michalick L, Lippert LJ, Kostevc T, Gäbel C, Schneider M, Streitz M, Demichev V, Gemünd I, Barone M, Tober-Lau P, Helbig ET, Hillus D, Petrov L, Stein J, Dey HP, Paclik D, Iwert C, Mülleder M, Aulakh SK, Djudjaj S, Bülow RD, Mei HE, Schulz AR, Thiel A, Hippenstiel S, Saliba AE, Eils R, Lehmann I, Mall MA, Stricker S, Röhmel J, Corman VM, Beule D, Wyler E, Landthaler M, Obermayer B, von Stillfried S, Boor P, Demir M, Wesselmann H, Suttorp N, Uhrig A, Müller-Redetzky H, Nattermann J, Kuebler WM, Meisel C, Ralser M, Schultze JL, Aschenbrenner AC, Thibeault C, Kurth F, Sander LE, Blüthgen N, Sawitzki B; PA-COVID-19 Study Group. Complement activation induces excessive T cell cytotoxicity in severe COVID-19. Cell 2022;185:493-512.e25. [PMID: 35032429 DOI: 10.1016/j.cell.2021.12.040] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
13 Kurano M, Ohmiya H, Kishi Y, Okada J, Nakano Y, Yokoyama R, Qian C, Xia F, He F, Zheng L, Yu Y, Jubishi D, Okamoto K, Moriya K, Kodama T, Yatomi Y. Measurement of SARS-CoV-2 Antibody Titers Improves the Prediction Accuracy of COVID-19 Maximum Severity by Machine Learning in Non-Vaccinated Patients. Front Immunol 2022;13:811952. [DOI: 10.3389/fimmu.2022.811952] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Suzuki T, Asai Y, Ide S, Fukuda S, Tanaka A, Shimanishi Y, Takahashi K, Terada M, Sato L, Sato M, Inada M, Yamada G, Miyazato Y, Akiyama Y, Nomoto H, Nakamoto T, Nakamura K, Togano T, Morioka S, Kinoshita-Iwamoto N, Saito S, Kutsuna S, Ohmagari N. Factors associated with high antibody titer following coronavirus disease among 581 convalescent plasma donors: A single-center cross-sectional study in Japan. J Infect Chemother 2021:S1341-321X(21)00281-6. [PMID: 34756573 DOI: 10.1016/j.jiac.2021.10.012] [Reference Citation Analysis]
15 Cimolai N. Passive Immunity Should and Will Work for COVID-19 for Some Patients. Clin Hematol Int 2021;3:47-68. [PMID: 34595467 DOI: 10.2991/chi.k.210328.001] [Reference Citation Analysis]
16 Bauernfeind S, Salzberger B, Hitzenbichler F, Scigala K, Einhauser S, Wagner R, Gessner A, Koestler J, Peterhoff D. Association between Reactogenicity and Immunogenicity after Vaccination with BNT162b2. Vaccines (Basel) 2021;9:1089. [PMID: 34696197 DOI: 10.3390/vaccines9101089] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
17 Wouters E, Verbrugghe C, Devloo R, Debruyne I, De Clippel D, Van Heddegem L, Van Asch K, Van Gaver V, Vanbrabant M, Muylaert A, Compernolle V, Feys HB. A novel competition ELISA for the rapid quantification of SARS-CoV-2 neutralizing antibodies in convalescent plasma. Transfusion 2021;61:2981-90. [PMID: 34498761 DOI: 10.1111/trf.16652] [Reference Citation Analysis]
18 Tosta E. The protective immunity induced by SARS-CoV-2 infection and vaccination: a critical appraisal. Explor Immunol. [DOI: 10.37349/ei.2021.00014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
19 Markmann AJ, Giallourou N, Bhowmik DR, Hou YJ, Lerner A, Martinez DR, Premkumar L, Root H, van Duin D, Napravnik S, Graham SD, Guerra Q, Raut R, Petropoulos CJ, Wrin T, Cornaby C, Schmitz J, Kuruc J, Weiss S, Park Y, Baric R, de Silva AM, Margolis DM, Bartelt LA. Sex Disparities and Neutralizing-Antibody Durability to SARS-CoV-2 Infection in Convalescent Individuals. mSphere 2021;6:e0027521. [PMID: 34431693 DOI: 10.1128/mSphere.00275-21] [Cited by in F6Publishing: 16] [Reference Citation Analysis]
20 Dolscheid-Pommerich R, Bartok E, Renn M, Kümmerer BM, Schulte B, Schmithausen RM, Stoffel-Wagner B, Streeck H, Saschenbrecker S, Steinhagen K, Hartmann G. Correlation between a quantitative anti-SARS-CoV-2 IgG ELISA and neutralization activity. J Med Virol 2022;94:388-92. [PMID: 34415572 DOI: 10.1002/jmv.27287] [Cited by in Crossref: 4] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
21 Göbel CH, Heinze A, Karstedt S, Morscheck M, Tashiro L, Cirkel A, Hamid Q, Halwani R, Temsah MH, Ziemann M, Görg S, Münte T, Göbel H. Clinical characteristics of headache after vaccination against COVID-19 (coronavirus SARS-CoV-2) with the BNT162b2 mRNA vaccine: a multicentre observational cohort study. Brain Commun 2021;3:fcab169. [PMID: 34405142 DOI: 10.1093/braincomms/fcab169] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
22 Göbel CH, Heinze A, Karstedt S, Morscheck M, Tashiro L, Cirkel A, Hamid Q, Halwani R, Temsah MH, Ziemann M, Görg S, Münte T, Göbel H. Headache Attributed to Vaccination Against COVID-19 (Coronavirus SARS-CoV-2) with the ChAdOx1 nCoV-19 (AZD1222) Vaccine: A Multicenter Observational Cohort Study. Pain Ther 2021. [PMID: 34313952 DOI: 10.1007/s40122-021-00296-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Steiner S, Schwarz T, Corman VM, Sotzny F, Bauer S, Drosten C, Volk HD, Scheibenbogen C, Hanitsch LG. Reactive T Cells in Convalescent COVID-19 Patients With Negative SARS-CoV-2 Antibody Serology. Front Immunol 2021;12:687449. [PMID: 34322120 DOI: 10.3389/fimmu.2021.687449] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
24 Mühlemann B, Thibeault C, Hillus D, Helbig ET, Lippert LJ, Tober-Lau P, Schwarz T, Müller MA, Witzenrath M, Suttorp N, Sander LE, Drosten C, Jones TC, Corman VM, Kurth F; Pa-COVID-19 collaborative study group. Impact of dexamethasone on SARS-CoV-2 concentration kinetics and antibody response in hospitalized COVID-19 patients: results from a prospective observational study. Clin Microbiol Infect 2021:S1198-743X(21)00327-X. [PMID: 34139335 DOI: 10.1016/j.cmi.2021.06.008] [Reference Citation Analysis]
25 Vicenti I, Gatti F, Scaggiante R, Boccuto A, Modolo E, Zago D, Basso M, Dragoni F, Bartolini N, Zazzi M, Parisi SG. Time Course of Neutralizing Antibody in Health Care Workers With Mild or Asymptomatic COVID-19 Infection. Open Forum Infect Dis 2021;8:ofab312. [PMID: 34295945 DOI: 10.1093/ofid/ofab312] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
26 Kohmer N, Rühl C, Ciesek S, Rabenau HF. Utility of Different Surrogate Enzyme-Linked Immunosorbent Assays (sELISAs) for Detection of SARS-CoV-2 Neutralizing Antibodies. J Clin Med 2021;10:2128. [PMID: 34069088 DOI: 10.3390/jcm10102128] [Cited by in Crossref: 1] [Cited by in F6Publishing: 18] [Article Influence: 1.0] [Reference Citation Analysis]